A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Bogota D.C., 110131, Colombia
Himeji-shi, 670-8520, Japan
Kurume-shi, 830-0011, Japan
Toon-shi, 791-0295, Japan
Changwon-si, 51353, South Korea
Muang, 22000, Thailand
Muang, 50200, Thailand
Mueang, 20000, Thailand
Naimuang, 30000, Thailand
Goztepe Istanbul, Turkey (Türkiye)